AMENDMENTS TO THE SPECIFICATION:

Please substitute the paper and computer readable form (CRF) of the Sequence Listing submitted herewith, for the paper and CRF of the Sequence Listing previously submitted in this application.

Please delete the "Study schematic" which appears between lines 5 and 6 in paragraph 1 on page 11.

Page 14, please replace the paragraph appearing at lines 7-10 with the following amended paragraph:

Nucleotide sequence surrounding the (-511) I L-1β polymorphism

Gene	Position	Allele 1	Allele 2	Surrounding Sequence
IL-1β	-511	C	T	CTGCAATTGACAGAGAGCTCC[C,T]GAGGCAGAGA ACAGCACCCAAGGTAGAGACCCA (SEQ ID No.9)

Page 14, please replace the paragraph appearing at lines 19-22 with the following amended paragraph:

Nucleotide sequence surrounding the (-31) I L-1β polymorphism

Gene	Position	Allele 1	Allele 2	Surrounding Sequence
IL-1β	-31	C	T	TCCTACTTCTGCTTTTGAAAGC[T,C]ATAAAAACAGC GAGGGAGAAACTGGCAGATACCAAACCTC (SEQ ID No.10)

Please replace the fourth full paragraph of page 2 (which corresponds with paragraph [0010] in Published Application 20060246439 with the following amended paragraph:

[0010] The present invention overcomes this problem by providing a method to determine the degree of serum cholesterol elevation which will occur in a patient during treatment with an immunosuppressant medication comprising: determining for the two copies of the IL-1 β gene present in the patient the identity of the nucleotide pair at the polymorphic site -511 C →T (position 1423 of ~~sequence X04500~~ SEQ ID No.11) of the IL-1β gene; and assigning the patient to a high cholesterol elevation group if both pairs are AT, assigning the patient to an intermediate cholesterol elevation group if one pair is AT and one pair is GC and assigning the

patient to a low cholesterol elevation group if both pairs are GC.

Please replace the first paragraph of page 3 (which corresponds with paragraph [0011] in Published Application 20060246439 with the following amended paragraph:

[0011] In a further embodiment this invention provides another method to treat a patient with an immunosuppressive medication comprising: determining for the two copies of the IL-1 β gene present in the patient the identity of the nucleotide pair at the polymorphic site –511 C→T (position 1423 of ~~sequence X04500~~ SEQ ID No. 11) of the IL-1 β gene; and treating the patient with the immunosuppression medication if both pairs are GC and using alternative treatment if one pair is AT and one pair is GC or if both pairs are AT. The immunosuppressive medication may be selected from the list in Table 2 and may be everolimus. In addition this invention provides that the alternative treatment comprises the addition of a cholesterol-lowering medication chosen from those listed in Table 1.

Please replace the second paragraph of page 3 (which corresponds with paragraph [0012] in Published Application 20060246439 with the following amended paragraph:

[0012] In a further embodiment this invention provides a method to determine the degree of serum cholesterol elevation which will occur in a patient during treatment with an immunosuppressant medication comprising: determining for the two copies of the IL-1β gene present in the patient the identity of the nucleotide pair at the polymorphic site -31 T→ C (position 1903 of ~~sequence X04500~~ SEQ ID No. 11) of the IL-1 β gene; and assigning the patient to a high cholesterol elevation group if both pairs are CG, assigning the patient to an intermediate cholesterol elevation group if one pair is AT and one pair is GC and assigning the patient to a low cholesterol elevation group if both pairs are AT.

Please replace the third paragraph of page 3 (which corresponds with paragraph [0013] in Published Application 20060246439 with the following amended paragraph:

[0013] In a still further embodiment this invention provides a method to treat a patient with an immunosuppressive medication comprising: determining for the two copies of the IL-1β gene present in the patient the identity of the nucleotide pair at the polymorphic site -31 T→C (position 1903 of ~~sequence X04500~~ SEQ ID No.11) of the IL-1β gene; and treating the patient

with the immunosuppression medication if both pairs are AT and using alternative treatment if one pair is AT and one pair is GC or if both pairs are CG. The immunosuppressive medication may be selected from the list in Table 2 and may be everolimus. In addition the alternative treatment may comprise the addition of a cholesterol-lowering medication chosen from those listed in Table 1.

Please replace the paragraph bridging pages 12 and 13 with the following amended paragraph:

[0060] A total of 47 unique polymorphisms corresponding to 24 genes were analyzed for each clinical trial. Candidate genes involved in metabolism of the drug, hypercholesterolemia, hyperlipidemia, immunosuppression and inflammation were chosen for this study. SNP assays were designed using information from public databases, such as OMIM, the SNP Consortium, Locus Link and dbSNP, and the Third Wave Technologies, Inc. (TWT, Madison, Wis.) website (~~http://~~64.73.25.65:8080/coe/index.jsp). The resulting probe sets for the genotyping assay were generated by TWT. Genotyping was performed with 60 ng of genomic DNA using the INVADER® assay developed by TWT (9-10) according to the manufacturer's instructions. See Lyamichev et al., *Nat Biotechnol.*, Vol. 17, pp. 292-296 (1999); and Ryan, *Mol. Diagn.*, Vol. 4, pp. 135-144 (1999).

Please add the following new paragraph immediately before the Detailed Description of the Invention on page 5:

Figure 7: Study Schematic for the RAD B251 clinical trial.